Bausch Health Cos Sees Unusually Large Options Volume (NYSE:BHC)

Bausch Health Cos Inc. (NYSE:BHC) was the recipient of some unusual options trading activity on Thursday. Investors purchased 4,021 call options on the company. This is an increase of 134% compared to the average volume of 1,722 call options.

Bausch Health Cos Stock Up 29.0%

Shares of NYSE BHC opened at $6.04 on Friday. Bausch Health Cos has a 52-week low of $4.33 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The stock has a market cap of $2.26 billion, a P/E ratio of -2.04 and a beta of 0.42. The firm has a 50 day moving average price of $4.96 and a 200 day moving average price of $5.46.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 1,389.97%. Analysts expect that Bausch Health Cos will post 4.05 EPS for the current year.

Bausch Health Cos News Roundup

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Quarterly results beat expectations. Bausch Health reported adjusted earnings of $1.26 per diluted share, versus the $0.96 analyst consensus, while revenue reached approximately $2.83 billion-$2.85 billion, ahead of the roughly $2.59 billion estimate. Adjusted EPS rose 40% from the prior-year period, and GAAP net income attributable to the company was $258 million. Bausch Health Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Growth was broad-based. Consolidated revenue increased 13% on a reported basis and 11% organically, supported by Salix, Solta Medical and Bausch + Lomb. Adjusted EBITDA rose 28% to $1.075 billion, while operating cash flow totaled $517 million. The company also reported its thirteenth consecutive quarter of year-over-year revenue growth excluding Bausch + Lomb. Bausch Health Announces Second Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 outlook. Full-year revenue guidance was increased to $10.8 billion-$11.0 billion, above the approximately $10.7 billion consensus, alongside higher adjusted EBITDA and adjusted operating cash-flow guidance. Unusually heavy call-option activity may also indicate increased short-term bullish speculation. BHC Q2 Earnings Beat Estimates and 2026 View Raised
• Neutral Sentiment: Analysts continue to assess whether the improved results and guidance can be sustained, with one research update projecting weaker future earnings. Bausch Health’s high leverage and still-negative net margin remain important risks despite the earnings beat.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BHC. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Zacks Research downgraded Bausch Health Cos from a “hold” rating to a “strong sell” rating in a report on Friday, July 24th. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Finally, Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of Bausch Health Cos stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the sale, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. The trade was a 33.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caption Management LLC grew its stake in Bausch Health Cos by 101.1% in the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after acquiring an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Bausch Health Cos by 12,589.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Bausch Health Cos by 6,661.2% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares in the last quarter. Finally, Camelot Portfolios LLC bought a new position in shares of Bausch Health Cos during the 4th quarter valued at about $59,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.